Divided Dose of TRAVATAN®

• Status: Completed
• Trial end date: 2011-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the incremental dosing of travoprost ophthalmic solution versus once a day dosing of TRAVATAN® in lowering intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alcon Research
• Treatments: Ophthalmic Solutions; Pharmaceutical Solutions; Travoprost

Criteria

Inclusion Criteria:

• Patients with open-angle glaucoma or ocular hypertension who meet the following IOP criteria:

1. Mean IOP ≥ 24 mmHg in at least 1 eye, with the same eye qualifying at 8 AM at both Day 0 and Day 1;

2. Mean IOP ≤ 36 mmHg in both eyes at all time points on Day 0 and Day 1.

• Must sign an informed consent form.

• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Females of childbearing potential who are pregnant, test positive on urine pregnancy test at the Screening Visit, intend to become pregnant during the study period, are breast-feeding, or are not using highly effective birth control measures.

• Current or history of ocular inflammation or infection in either eye within the past 3 months.

• Corneal thickness greater than 620 µm as determined by pachymetry in either eye.

• Severe visual field loss.

• Cup to disc ratio greater than 0.8 in either eye.

• Intraocular surgery within the past 6 months in either eye.

• Other protocol-defined exclusion criteria may apply.